Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

iBio, Inc.

CIK 1420720 IBIO·Pharmaceutical Preparations · All EDGAR filings ↗

Material weakness Filing comparison

iBio, Inc. reported internal control effective again after a material weakness

Material weakness in internal control Internal control reported effective

The weakness was first reported on 2023-09-27 — 1066 days and 4 annual reports before this one.

Management has performed an assessment of the effectiveness of iBio’s internal control over financial reporting as of June 30, 2026, based upon criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 COSO Framework). Based on this assessment, management has concluded that our internal control over financial reporting was effective as of June 30, 2026. Changes in Internal Control Over Financial Reporting Except as otherwise…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-09-05
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
No
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
4
Weakness days reported
1066
Weakness first reported
2023-09-27
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.